Boditech Med Inc.
Financials
Valuation Metrics
Boditech Med Inc.'s Market Cap is ₩2048B. At end of 2025 it was ₩2874B. Ranked #843 of 2,421 in KR market (top 35%), #390 of 1,640 on KOSDAQ (top 24%), #25 of 96 in Health Care Equipment & Services (top 26%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 204.84B KRW | KR#843/2,421 Sec#25/96 |
| Revenue | 174.78B KRW | KR#1,104/2,421 Sec#15/96 |
| Net Income | 26.31B KRW | KR#600/2,421 Sec#13/96 |
| Total Assets | 303.62B KRW | KR#1,030/2,421 Sec#22/96 |
| Net Assets | 261.45B KRW | KR#793/2,421 Sec#18/96 |
| Employees | 532 | KR#467/2,421 Sec#7/96 |
| Value | ||
| P/E | 7.79x | KR#646/2,421 Sec#17/96 |
| P/B | 0.78x | KR#1,237/2,421 Sec#29/96 |
| PEG | 0.01x | KR#110/2,421 Sec#4/96 |
| P/S | 1.17x | KR#1,486/2,421 Sec#36/96 |
| EV/EBITDA | 7.45x | KR#423/2,421 Sec#14/96 |
| FCF Yield | -5.34% | KR—/2,421 Sec—/96 |
| Profitability | ||
| ROE | 10.06% | KR#610/2,421 Sec#26/96 |
| ROA | 8.67% | KR#371/2,421 Sec#21/96 |
| Op. Margin | 15.28% | KR#292/2,421 Sec#22/96 |
| Revenue Growth | 16.99% | KR#627/2,421 Sec#34/96 |
| Earnings Growth | 701.19% | KR#87/2,421 Sec#4/96 |
| Financial Health | ||
| Debt Ratio | 16.13% | KR#280/2,421 Sec#17/96 |
| Total Debt | 32.43B KRW | KR#1,185/2,421 Sec#28/96 |
| FCF | -10.93B KRW | KR#1,736/2,421 Sec#65/96 |
| Cash | 38.40B KRW | KR#875/2,421 Sec#21/96 |
| Current Ratio | 5.46x | KR#254/2,421 Sec#21/96 |
| Net Debt/EBITDA | -0.22x | KR#563/2,421 Sec#22/96 |
| Dividend | ||
| Div. Yield | 1.61% | KR#969/2,421 Sec#25/96 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | -35.65% | KR#1,723/2,421 Sec#52/96 |
| 1M Return | -8.33% | KR#2,021/2,421 Sec#74/96 |
| From 52W High | -37.67% | KR#825/2,421 Sec#24/96 |
| 1Y MDD | -36.44% | KR#447/2,421 Sec#10/96 |
| Trading | ||
| Volume | 19,781 shares | KR#1,592/2,421 Sec#57/96 |
| Trading Value | 184.7M KRW | KR#1,312/2,421 Sec#52/96 |
| Foreign Own. | 3.52% | KR#1,147/2,421 Sec#38/96 |
| Per Share | ||
| EPS | 1,201 KRW | KR#647/2,421 Sec#13/96 |
| BPS | 11,934 KRW | KR#858/2,421 Sec#17/96 |
Company Info
Boditech Med, established in 1998 as an in-vitro diagnostics specialist, operates production corporations in the US and China, expanding its diagnostics market. Leveraging lateral flow immunofluorescence technology, the company possesses over 100 types of disease diagnostic product lines and has diversified sales channels by establishing sales networks in over 130 countries worldwide. It has developed next-generation and automated immunoassay platforms, laying the groundwork for entry into advanced markets and large hospitals, and is aspiring to become a global diagnostics company through the development of high-value-added diagnostic cartridges. Its headquarters are in Chuncheon-si, Gangwon-do.